Sarepta Therapeutics stock faces a USD 5.00 Sell target

Published on 10/07/2026 at 07:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sarepta Therapeutics stock drew a USD 5.00 Sell target from HC Wainwright on October 6, 2026. Q2 revenue reached USD 401.251 million despite a GAAP loss.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics stock (ISIN US8036071004) was last at USD 17.31 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 1.03 percent from the prior close. The latest analyst action put the biotechnology company back under pressure, with HC Wainwright reiterating a Sell rating and a USD 5.00 price target, according to MarketBeat on October 6, 2026.

Sell target highlights the divide

The USD 5.00 target stands 71.11 percent below the October 6 price, a gap that sharply contrasts with the broader analyst range. MarketBeat reported seven Buy ratings, seven Hold ratings and seven Sell ratings, producing a Hold consensus and an average target of USD 22.71.

The latest company update came on September 30, 2026, when Sarepta presented new ELEVIDYS data at the World Muscle Society Annual Congress, according to Sarepta Therapeutics. The release described clinically meaningful functional benefit in older ambulatory patients with Duchenne muscular dystrophy.

Quarterly figures show the risk

Sarepta reported Q2 2026 revenue of USD 401.251 million and a GAAP net loss of USD 4.89 million. Revenue fell 34.3 percent year over year, while adjusted EPS of USD 0.64 exceeded the USD 0.22 consensus estimate, according to MarketBeat. The contrast leaves revenue recovery and ELEVIDYS demand as the central operating questions for the stock.

Wells Fargo analyst Yanan Zhu maintained a Buy rating with a USD 38.00 target on October 2, 2026, while H.C. Wainwright reiterated its Sell view, Markets Insider reported on October 5, 2026. That spread shows why the clinical data and product sales trajectory matter more than a single rating label.

SRPT remains below its yearly high

The stock's October 6 range was USD 17.04 to USD 17.64, with volume of 2,691,377 shares. Its 52-week range was USD 14.68 to USD 25.32, placing the last price USD 8.01 below the high and USD 2.63 above the low.

At USD 1.8 billion in market capitalization as of October 6, 2026, Sarepta remains a commercial-stage biotechnology company focused on genetic medicines for rare diseases. The next quarterly report is scheduled for November 4, 2026.